Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Donidalorsen→

Donidalorsen PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2304692-48-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Prekallikrein-directed antisense oligonucleotide (ASO)GalNAc-conjugated RNA-targeting therapy
Mechanism of action
A GalNAc-conjugated antisense oligonucleotide that binds prekallikrein (KLKB1) mRNA and induces RNase H1-mediated degradation, reducing prekallikrein protein and downstream plasma kallikrein/bradykinin generation.
Indications / reported uses
  • Prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and paediatric patients aged 12 years and older under the US FDA indication approved August 21 2025

Sources: US DailyMed — DAWNZERA (donidalorsen), updated September 24 2025 · US FDA — DAWNZERA approval details · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Prekallikrein-directed antisense oligonucleotide (ASO); GalNAc-conjugated RNA-targeting therapy

Mechanism of action

A GalNAc-conjugated antisense oligonucleotide that binds prekallikrein (KLKB1) mRNA and induces RNase H1-mediated degradation, reducing prekallikrein protein and downstream plasma kallikrein/bradykinin generation.

General use cases

  • Prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and paediatric patients aged 12 years and older under the US FDA indication approved August 21 2025

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Donidalorsen PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Donidalorsen Permitted Daily Exposure (PDE) report (the Donidalorsen PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Donidalorsen Occupational Exposure Limit (OEL) report (the Donidalorsen OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.